6 Results for "

MDA-MB-157

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "MDA-MB-157" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-172957
Target:  

JAK

Research Areas:  

Cancer

JNN-5 is a potent and selective JAK2 inhibitor with an IC50 of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .
loading...
    loading...
Cat. No.: HY-120372
CAS No.: 1584631-89-9
Target:  

Notch

Research Areas:  

Cancer

BMS-871 is an orally active pan-Notch inhibitor with IC50 values ​​of 4/1/4/3 nM for Notch1/2/3/4, respectively. BMS-871 significantly inhibited the proliferation of TALL-1 and MDA-MB-157 cells and demonstrated significant antitumor activity in T-acute lymphoblastic leukemia and triple-negative breast cancer xenograft models. BMS-871 can be used to study leukemia and breast cancer .
loading...
    loading...
Cat. No.: HY-158683
Research Areas:  

Cancer

KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-162531
CAS No.: 3034541-82-4
Research Areas:  

Cancer

KIF18A-IN-9 (Compound 1) is a potent KIF18A inhibitor, with an IC50 value of 3.8 nM. KIF18A-IN-9 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
loading...
    loading...
Cat. No.: HY-162532
CAS No.: 3034542-28-1
Research Areas:  

Cancer

KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC50 value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
loading...
    loading...
Cat. No.: HY-181035
Target:  

PROTACs CDK

Research Areas:  

Cancer

DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance .
loading...
    loading...